The next generation of treatment? Could psychedelic research be a promising new step in treating mental health disorders like depression, anxiety and PTSD? Back in
The Transatlantic Growth campaign (TAG) is an annual campaign that highlights and celebrates businesses that demonstrate growth and investment on both sides of the Atlantic.
MAC Clinical Research featured in a recent Guardian article titled: Clinical trials: how taking the pills may pay those bills. The article highlights how companies
To continue to meet the research needs of our clients and their patients across the globe, MAC Clinical Research has arrived in the United States!
MAC’s Senior Director of Early Phase Research, Dr Peter Dewland, has been awarded the Faculty of Pharmaceutical Medicine President’s Medal. After qualifying in Biochemistry and
October 24, 2018 MANCHESTER, ENGLAND Across every clinical trial, Pharma and Biotech have a dire need to access patients in efficient numbers and to conduct their
Defying Dementia is raising funds for Dementia research.
MAC Neuroscience Centre of excellence, the early phase division of MAC Clinical Research, has been awarded Accreditation from the Medicines and Healthcare products Regulatory Agency (MHRA).
A new drug developed by Lancaster University which may help to prevent the early stages of Alzheimer’s disease is to enter clinical trials. Lancaster University has filed a patent application for the drug, and it will be progressing into clinical trials run by the north-west research company MAC Clinical Research.
MAC Clinical Research has opened a new phase I/IIa clinic at Citylabs in Manchester, expanding its phase I services in the United Kingdom. This brand
